) UCSD Cancer Center's Viral Malignancy Program consists of 12 Members, representing total peer-reviewed funding of $5,511,293 in annual direct costs. During the last year, its Members produced a total of 42 cancer-relevant, peer-reviewed publications, 31% of which were intra- and inter-programmatic collaborations. Research on viral malignancies presents a unique opportunity for our understanding of oncogenesis and a means for targeted intervention. Viruses now etiologically associated with human malignancy include: Epstein-Barr virus (EBV) [non-Hodgkin's lymphoma (NHL) and nasopharyngeal carcinoma]; Hepatitis B and C viruses (HBV and HCV) [hepatocellular carcinoma (HCC)]; Human Immunodeficiency Virus, type 1 (HIV-1) [Kaposi's sarcoma (KS), NHL, and cervical carcinoma in situ]; Human Papilloma Virus (HPV) [skin, genital, and esophageal cancers); Human T-lymphotropic Virus, Type I [adult T-cell leukemia/lymphoma (ATLL)]; and the recently disco vered Human Herpesvirus, Type 8 (HHV-8) [Kaposi's sarcoma, body cavity lymphoma, and possibly multiple myeloma]. The Viral Malignancy Program at the UCSD Cancer Center consists of a longstanding cohesive group of researchers, with wide-ranging expertise in oncogenic viruses. The current primary interests of the Program Members are focused on human retroviruses (including both HIV and HTLV), EBV, and HHV-8, and Members view their association with the Cancer Center as: Helpful to accelerating the development of research collaborations to investigate the pathogenesis of malignancies induced by these viruses. Providing access to rare and valuable shared resources to drive current investigations, develop inter-programmatic investigations, and foster long-term goals. A venue for testing reagents developed to combat these oncogenic viruses and/or their associated malignancies. A pathway to forging new investigative partnerships with prevention and control scientists to study the best methods for combating the spread of malignancy as an infectious disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69
Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089
Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809
Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev :
Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36
Ramdani, Ghania; Schall, Nadine; Kalyanaraman, Hema et al. (2018) cGMP-dependent protein kinase-2 regulates bone mass and prevents diabetic bone loss. J Endocrinol 238:203-219
Nguyen, Vi; Marmor, Rebecca A; Ramamoorthy, Sonia L et al. (2018) The Use of Solicited Publishing by Academic Surgeons. Surgery 164:212-218
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609
Pandolfi, Erica C; Hoffmann, Hanne M; Schoeller, Erica L et al. (2018) Haploinsufficiency of SIX3 Abolishes Male Reproductive Behavior Through Disrupted Olfactory Development, and Impairs Female Fertility Through Disrupted GnRH Neuron Migration. Mol Neurobiol 55:8709-8727
Galanina, Natalie; Goodman, Aaron M; Cohen, Philip R et al. (2018) Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res 6:1129-1135

Showing the most recent 10 out of 862 publications